HepaRegeniX, founded in 2015, specializes in the discovery and development of small molecule kinase inhibitors. The management team, led by Dr. Wolfgang Albrecht, and scientific advisors have over 20 years of experience in the pharmaceutical industry with a proven track record in drug development and cover all disciplines along the value creation chain from early stage discovery through clinical proof-of-concept studies. The unique therapeutic concept for the treatment of liver diseases was discovered by Prof. Lars Zender and his research group at the University Hospital Tubingen, Germany. Investors in HepaRegeniX include the Boehringer Ingelheim Venture Fund (BIVF), Novo A/S, coparion, High-Tech Gruenderfonds and Ascenion GmbH. Ascenion supported the acquisition of the exclusive IP rights.
HepaRegeniX GmbH secures Series B Financing in excess of €11 Mio. to advance first drug candidate to the clinic
HepaRegeniX GmbH Raises €9 million in a Series A Financing to Develop Kinase Inhibitors for the Treatment of Acute and Chronic Liver Diseases
Info & Contact
- Dr. Wolfgang Albrecht